Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds like you are onto something Goldy, for sure worth additional research. They extended the offering deadline again. No surprise given current pps.
At the last offering I added a bunch of shares to my position. Shares I really cant afford right now but I came up with the money to take advantage.
The offering allows you to add shares easily, efficiently, quickly with out running the price up.
Very nice reply Goldy, and thank you. Yes, I'm aware of Section 1202 qualified gain exclusion, and you are correct in that subscription rights purchase should be considered original issue so there's more to this than looking strictly at share price.
I think the issue with at least some of us shareholders is the year-after-year hype with no revenue deals in place. Once again we are being told 2022, possibly 2023 for a deal to take place. Had this been, say, 3 or 4 years ago and only my second bite at the apple, I probably would have jumped on the opportunity, regardless of PPS (within reason). I've done similar in the past.
But after 5 years now and having gone through many cycles of "dollar-land any day now" hype with no dollar-land or anything close coming to fruition, not too excited about the offering - especially at or higher than current PPS. Sort of like dollar averaging on a falling stock price trying to catch a falling knife... whose price never comes back up. You reach a point where you have to say to yourself, "Am I just throwing good money after bad?". That's where many of us are with ALRT. But again, thanks for the thoughtful msg. And who knows... maybe the next time (if) the Rights come around again, I'll jump on it. LOL. GLTU!
News! ALR Technologies Announces Completion of Pivotal Non-Inferiority Study on the GluCurve Pet CGM
March 15, 2022 08:28 ET | Source: ALR Technologies
SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today announced successful results from the conclusion of the non-inferiority study conducted on the GluCurve Pet CGM which was previously announced on February 10, 2022 and February 28, 2022. GluCurve is the first of its kind Continuous Glucose Monitor (CGM) specifically for diabetic cats and dogs.
Notable findings from the study:
Utilizing a chemistry analyzer as the baseline, the GluCurve Pet CGM was more accurate than the leading Blood Glucose Meter (BGM) for animals 47.8% of the time.
100% of the GluCurve Pet CGM readings paired to the chemistry analyzer reference values were within ±20%, compared to 86.9% from the animal BGM
The GluCurve Pet CGM’s average deviation from the baseline was 9.7% compared to 8.2% from the animal BGM.
No clinically significant differences were found when comparing the GluCurve Pet CGM to the chemistry analyzer or leading animal BGM.
GluCurve displayed otherwise unavailable data on insulin injection times, eating habits, activity, and stress seen through changes in glucose on a day-to-day basis.
Dr. Imperato, lead veterinarian in the study commented, “The GluCurve Pet CGM plugs a long-standing gap in managing veterinary diabetic patients; not only will veterinarians finally receive effortlessly accurate data, the patients will live longer too.”
“The non-inferiority study further demonstrates the significant need for GluCurve in veterinary medicine. The in-home data collected is invaluable to veterinarians and by analyzing and organizing it into effective patient management it greatly reduces the effort and time needed by clinicians to treat diabetic pets,” said Sidney Chan, Chairman and CEO of ALR Technologies. “Now that we have the successful results of the non-inferiority study, a MOU for manufacturing with a definitive agreement in the works, and conducted preliminary discussions with the leading animal health pharmaceutical companies, we are well positioned to start realizing the full potentials of ALRT. We will now focus our attention on completing a partnership agreement in the near future to commercially launch GluCurve Pet CGM in a meaningful way in Q3 2022.”
About ALR Technologies
ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives healthcare providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division has identified an unmet need in diabetes care and has developed GluCurve; a solution to assist Veterinarian Doctors to determine the efficacy of insulin and to help to identify the appropriate dose and frequency of administration of insulin for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.
On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore. More information about ALR Technologies Inc. can be found at www.alrt.com. Information regarding ALR Technologies SG Pte. Ltd. can be found at https://sg.alrt.com.
Long time lurker, first time poster.
It's true the subscription right may be the same or lower then the current market price for the stock. However, if a right holder sees any value in adding to their position, they would be wise to consider exercising the right - as opposed to buying shares on the open market (at least speaking from the perspective of a US Taxpayer).
Check out Section 1202 of the Internal Revenue Code - "Partial Exclusion from Gain for Certain Small Business Stock"
There are many requirements needed to qualify for this exclusion. But the biggest/hardest one, in my opinion, is having a position that qualifies as "original issue". Buying on the secondary market is not "original issue", but a Rights offering, sounds like an "original issuance" to me. It's not often you can get an opportunity to acquire an "Original Issue" stock, so it may be worthwhile to pay a premium on the exercise (if there is a premium at all) to potentially qualify for this gain exclusion in the future.
I'm not an investment advisor/1202 expert, just a normal guy who invests in stocks. So you obviously have to consult your own advisory team/do your own due diligence. But I just wanted to share this to provide some food for thought.
Who knows. Maybe Chan knows it does qualify and he keeps trying to give the stockholders an opportunity to get in (continually re-opening/extending the rights offerings)?? Wishful thinking most likely, but maybe it's not...
Meanwhile, the share price is still below the subscription rights offer and there's little interest in this company. Obviously, if Chan ever gets a significant revenue deal that will all change. But that's still a big "if".
At this point I want to take my money out and put it into some movers, but will take weeks to sell all for a loss
Good post, I couldn't agree more
First of all, LOS' pet population with diabetes is off by a factor of 2. Considering there are approximately 76.8M dogs and 58.4M cats in the US, and it is estimated that 1 in 300 dogs and 1 in 230 cats have diabetes, that amounts to roughly 0.5M dog and cat "pets" that even have diabetes... not 1.0M. As far as other pets like birds, ferrets, and the like.. forget about that.
Then, one has to take in consideration not 100% of these pet owners are going to even know their animal has diabetes, let alone treat them for it. Not to mention that many of the dogs and cats in this country are strays. ALRT will be lucky to capture 10% of this 0.5M population, even if they had 100% market share.
All of this is besides the point and you nailed it on the head. It's about the hype with these OTC's and I question the money being spent these past 5 years as well. LOS asks why we hang in there and haven't divested ourselves of our shares yet if we lack confidence in the company? He knows the answer to that. First of all, the trade volume is non-existent and trying to dump a 1/4 mil, 1/2 a mil, or millions of shares only drives the PPS way down and begs the investor to take a significant hit. Then, there's that "hope" that someday Chan & Co. will make "the deal" and we'll be able to recoup our investments or make a reasonable profit for hanging onto a speculative company this long.
I've bought into the cheer-leading on these OTC's too often. And ALRT is the last one for me. For everyone of these speculative companies that hit, 1,000 of them fail. And all the hype and cheer-leading in the world doesn't change that fact.
23 x 750k = about the same as ALRT. And developing software for consumer product companies is way easier route than seeking pharma and FDA approvals. Seeking partnerships takes time as well. I’m ok where we are now. Let’s go ALRT.
23 x 750k = about the same as ALRT. And developing software for consumer product companies is way easier route than seeking pharma and FDA approvals. Seeking partnerships takes time as well. I’m ok where we are now. Let’s go ALRT.
Best thing for the company would be to license their a1c predictive patent. Might be the only way we get revenue. If the company wants to be in vet clinics that a really hard thing. It isn't like hospital networks where one group owns multiple hospitals. It will cost millions to market to the vet clinics and years to get real adoption. My wife makes more revenue selling stuff on Facebook marketplace.
I've given up on OTC research, it's all about hype and this company lost it's hype right after FDA approval. Also I don't get how keeping this company afloat cost 20mil over 5 years, they spent 4mil a year and just have a phone app. A kid in college would build this app for 100k.
Market data means nothing if you haven't even entered the market.
How could somebody spend so much time complaining yet so little time researching the company they are complaining about? It is truly astounding.
There are only two companies selling CGMs (since Medtronic is basically out of the picture), Abbott and Dexcom. Dexcom is 4x the cost of Libre and priced out of the animal market and Libre will not sell to veterinarians or make an animal CGM. Literally one phone call to a veterinarians or one google search would tell you that information in minutes.
So please tell me what "big player" is going to spend a million dollars creating software for the next year and then when they do that please tell me how they are going to sell a CGM? Find me one manufacturer they could partner with anywhere in the world.
Just looking at the USA alone, there are 1 million diabetic animals. With no competition. ALRT will have 100% of the market as the ONLY pet cgm. If the animals use it 3 times a year that is 3,000,000 times $x amount of profit. If they even make $10 that is $30,000,000 and I assume they will make a lot more then that.
If you don't believe the animal market will make money you're a fool for staying invested in a company you think will fail. And if you do think it will make money why are you crying?
Rdizz - so did I, today. Not interested in 05 a share or in financing any more of Mr. Chan's debt. What I am interested in, after 5 years of holding this, is getting a damn return on my investment.
I can't believe it's costing 20mil to develop and sell a software product. I'm a developer with 10yrs experience. I was developing software for Aldi through a consulting firm for 7 of those years. My company only billed around $750k a year to them with 4 developers billing. What they have would take less than a year to replicate. The big players can hire two devs for $300k a year and catch up in no time
Just saw the rights offering in my brokerage account, anyone thinking of paying off chan's debt to the company haha
Perhaps the old Aesop fable "The Boy Who Cried Wolf" comes to mind, and can help explain why the latest PR didn't move the needle on share price. Just saying... GLTUA
Looking forward to the end of this month when we should see another PR about the Pet CGM partnership. I’m not worried, but am miffed that there isn’t more interest in this stock. The last PR was really exciting news. Keep up the good work, Mr Chan and company. Let’s go ALRT!
Yeah. I'm sure Chan would like to sell you a few million shares right now at 5¢. Go for it, big shooter. What's holding you back?
Rdizz - yes sir. I mean, what's $25K to a big shooter like johnglenn when he stands to become a zillionaire any day now? LOL. GLTU!
If you think it's going to skyrocket than even .10 would seem like a sale.
Not trying to argue, just being silly
Called my bluff? lol What bluff.
I can buy at .05 now and per the previous offer sounds like I can buy more at .05 in the future.
I would be willing to make a side wager that McVee will have an opportunity to sell at .08 cents.
LOL. Dollarland any day now!
Lol, called his bluff
LOL! Well, if you're so confident we're headed to dollar-land any day now, why not just buy my shares for $0.10 right now? Sounds like a steal to me
We will be having a party. Cant wait.
We will be celebrating a much higher pps and you selling all your shares.
Although I will kind of miss having you around.
You know the old story about Ifs and Buts, Candy and Nuts.
If they announce a partnership with a major pharma company you will get your .08 cents.
Looking forward to it.
My apologies. Checked limit and it's set at 08 (not 07), AON
Just confirming. If you have the opportunity to sell your shares at .07, you will?
"We are looking forward to reviewing the final results with our prospective pharmaceutical partner next month."
This right here. We all need to hope and pray this meeting goes very well.
Come on Mr. Chan, Mr. Stern and all the fine folks at Alr Technologies.
If they can put together the kind of deal they have mentioned in previous pr's.....it is going to be huge.
ALR Technologies Announces Successful Preliminary Results
for the GluCurve Pet CGM Non-Inferiority Study
( February 28, 2022 – Singapore) ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB:
ALRT), the diabetes management company, today announced preliminary results from the NonInferiority Study currently being conducted on the GluCurve Pet CGM (GluCurve).
Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with
the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements
set for human blood glucose meters in ISO: 15197:2013.
“We are pleased with GluCurve’s accuracy as compared to the leading pet BGM used by
veterinarians. The platform has provided valuable diagnostic information throughout the study
that would not be available from traditional in-clinic glucose curve. A significant benefit of
GluCurve is that it is applied in minutes in-clinic and the pet is sent home. GluCurve records
blood sugar levels every 3 minutes for up to 14 days while the pet and owner go about their
daily lives. This presents many benefits compared to BGM whereby 5 to 7 data points are
collected over 8-12 hours in a clinical setting. The process of housing a pet in-clinic and drawing
blood every 2 hours causes stress which elevates their blood glucose levels and is challenging
for the clinic staff to undertake. As part of the study, GluCurve was able to document the
impact on glucose levels from the stressful clinical experience required for BGM testing in real
time,” said Joe Stern, Head of Animal Health at ALR Technologies.
Mr. Stern continues, “The data collected by GluCurve is processed and organized to facilitate
clinicians in providing optimal care with ease. By comparing daily curves, the platform is able to
show clinicians if the pet is receiving insulin injections at the appropriate times, the pet’s eating
habits, and a complete view of the pet’s blood sugar levels over time. Additionally, we have
received feedback from the lead veterinarian in the study confirming what other veterinarians
and animal health companies have told us; they believe the GluCurve Pet CGM will become the
standard of care for the management of diabetic pets. We are looking forward to reviewing the
final results with our prospective pharmaceutical partner next month.
Sorry for the ugly format
Nor do I. Sooner or later, Mr. Chan is going to run out of lifeline to hold onto, and we'll all end up bag holders. I'm going against my better judgment and continue holding. GLTUA
Yeah I don't really blame them
Yeah I don't really blame them
Just a weak hand, think nothing of it.
Wtf what happened, someone got fed up and dumped
0275. Wow. Where are all the ALRT cheerleaders?
It's almost like they were responding to our recent board messages, we have to be the only ones seeing the prs
Great PR. Now at 042 with 8,900 shares traded today. Maybe the next PR can take us to 032! GLTUA. LOL.
This speaks to Mr Chan’ determination to see this through when others would have cashed out. He stayed on task far longer than most people here realize. Looking forward to great success in ‘22 and ‘23.
“A lot goes into the integration of such advanced hardware and software technologies, and our engineering and development team has done a phenomenal job completing the process in preparation for our upcoming non-inferiority study later this month,” says Sidney Chan, Chairman and CEO of ALRT. “This is another major milestone on the path to commercialization this summer which we anticipate will make ALRT cashflow positive in 2022.”
Absolutely, patience will pay off here. The final number that the 50% brings will be very interesting
What sticks out to me is the the partnership info, if they are selling 50% stake that could be worth tens of millions if not hundreds over whatever length of time its structured at. Plus if a major pharmaceutical company is taking over sales and marketing it will grow faster then a new company like ALRT trying to sell it on their own. If they resume talks in march I would think a deal could be finalized and announced as soon as April or maybe May. Either way, the finish lines is quickly approaching
Nothing but good news out of alrt , staying on track to deliver as promised!
NEWS! ALR Technologies Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human Initiatives
February 10, 2022 08:28 ET | Source: ALR Technologies
...
SINGAPORE, Feb. 10, 2022 (GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM.
GluCurve Pet CGM is a first of its kind CGM for diabetic cats and dogs that utilizes an adapted version of the ALRT Diabetes Solution platform for Veterinarian Doctors. The GluCurve mobile app collects and displays pet glucose data for the pet owner via Bluetooth from the CGM hardware and securely uploads the data to the cloud where the Company’s technologies analyze and organize the data into a convenient patient management portal for veterinarians. GluCurve offers veterinarians crucial time saving features such as glucose curve comparisons, insulin dose calculators, and information on all the available insulin therapies along with best practice guidelines.
Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM.
“A lot goes into the integration of such advanced hardware and software technologies, and our engineering and development team has done a phenomenal job completing the process in preparation for our upcoming non-inferiority study later this month,” says Sidney Chan, Chairman and CEO of ALRT. “This is another major milestone on the path to commercialization this summer which we anticipate will make ALRT cashflow positive in 2022.”
ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM.
The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.
About ALR Technologies
ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives healthcare providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division has identified an unmet need in diabetes care and has developed GluCurve; a solution to assist Veterinarian Doctors to determine the efficacy of insulin and to help to identify the appropriate dose and frequency of administration of insulin for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.
On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore. More information about ALR Technologies Inc. can be found at www.alrt.com. Information regarding ALR Technologies SG Pte. Ltd. can be found at https://sg.alrt.com.
Contact
Ken Robulak (US)
Phone: +1 (727) 736-3838
Anthony Ngai (Singapore)
Phone: +65 3129 2924
Email: ir@alrt.com
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain “forward-looking statements” as defined under applicable securities legislation. All information and statements contained herein that are not clearly historical in nature constitute forward-looking information, and the words “anticipate”, “estimate”, “believe”, “continue”, “could”, “expect”, “intend”, “plan”, "postulates", "predict", “will”, “may” or similar expressions suggesting future conditions or events or the negative of these terms are generally intended to identify forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Specifically, but not limited to, there is no assurance that the Company will commercialize the GluCurve CGM in 2022, or thereafter, have revenues, earnings, and positive cashflows from the sale of the GluCurve CGM, enter into a strategic agreement with a pharmaceutical for the GluCurve CGM, commence trials for CGM for human health in 2022 or thereafter, apply for FDA clearance to market CGM for human health, or commercialize CGM for human health thereafter. The forward-looking statements included in this news release are made as of the date hereof. ALR Technologies disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Sure Buzz. Like I trust the Joe Biden process. LOL
Trust the process.
Followers
|
148
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
13383
|
Created
|
10/05/09
|
Type
|
Free
|
Moderators |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |